Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder

Overactive bladder (OAB) is associated with systemic chronic inflammation. Indices derived from complete blood count (such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)) have shown associations with OAB presence. However, whether baseline inflammatory status predicts response to beta-3 adrenergic agonist therapy remains untested. This prospective observational cohort study evaluates the predictive ability of baseline NLR, PLR, and SII for 3-month treatment response to mirabegron 50 mg in women with OAB.

Inclusion Criteria: * Female patients aged 18 years or older * Overactive bladder symptoms for at least 3 months * Mirabegron 50 mg planned by physician decision within routine care * Ability to provide written informed consent Exclusion Criteria: * Any previous OAB-specific treatment other than behavioral therapy (oral antimuscarinic or beta-3 agonist, intravesical botulinum toxin, sacral neuromodulation, or posterior tibial nerve stimulation) * Acute infection within the last 4 weeks, including culture-confirmed urinary tract infection * Chronic inflammatory disease (rheumatologic or autoimmune disease, or inflammatory bowel disease) * Active malignancy or cancer treatment within the last 5 years * Use of systemic glucocorticoids within the last 4 weeks, or chronic NSAID or immunosuppressive use * Conditions affecting lower urinary tract function other than OAB (neurogenic bladder, urinary tract stones, history of pelvic radiotherapy or bladder surgery, pelvic organ prolapse stage 3 or higher, or stress-predominant mixed urinary incontinence) * Known diagnosis of hematologic disease, anemia (Hb\